logo
ScreenersREIT EarningsREIT SectorsMarketplaceLearn
Logo

Syndax Pharmaceuticals, Inc.

SNDX

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDā€¦ read more

Healthcare

Biotechnology

7 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$15.74

Price

+6.86%

$1.01

$14.73

Previous Close

$14.80

Open

Premium

52w Discount
Market Cap

$1.356b

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$78.180m

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$334.988m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

-$3.90

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

$157.424m

$596.149m

Assets

$438.725m

Liabilities

$1.675m

Debt
Debt to Assets

0.3%

-

Debt to EBITDA
Free Cash Flow

-$302.667m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
ā†‘ TopSummaryPriceFinancialsPress Releases
logo
About usFAQ
All the information presented is collected from official and public documents such as: Quarterly and Annual Reports, 10-K (US), Information Form (Canada), Presentations and the Investor Relations (IR) section of the company's website.
The data displayed by alreits.com is solely for informational purposes, we do not recommend the buying, holding or selling of any of the stocks on the website. If you have no experience in the stock market, please talk to your personal licensed investment advisor before making any decisions.